Government spokesman says the attack in Khost destroyed a civilian home, killing five boys, four girls and a woman.
Published On 25 Nov 2025
At least nine children and a woman have been…
Author: admin
-
Baker McKenzie Advises Current Shareholders (Including Funds Advised by ARCHIMED as Controlling Shareholder) on the Sale of Citieffe Group to PolyMed | Newsroom
Baker McKenzie advised the current shareholders on the sale of all their equity interests in Medistream SA, a Swiss corporation holding all equity interests in Citieffe SRL, an Italian medical devices manufacturer, and its subsidiaries in the United States and Mexico (“Citieffe Group”), to Poly Medicure B.V., Amsterdam, Netherlands, a wholly owned subsidiary of Poly Medicure Limited, an Indian public company (“PolyMed”). Funds advised by ARCHIMED, a global private equity firm focused on the healthcare sector, were the majority shareholders in Citieffe Group.The Citieffe Group is an Italy-based manufacturer specializing in the orthopedic trauma and extremities segment, with a direct presence in Italy, the United States and Mexico, as well as distribution across 25 countries. The transaction was completed on 6 November 2025.
This strategic acquisition provides PolyMed with a gateway into the global orthopedics market, particularly in the trauma and extremities segment — the fastest growing and most resilient category within orthopedics. As part of PolyMed, the Citieffe Group is expected to benefit from enhanced R&D and manufacturing capabilities, including potential cost efficiencies through operations in India.
Baker McKenzie advised the shareholders of Citieffe Group, including ARCHIMED, on all legal and tax aspects of the transaction.
M&A Partners Alexander Fischer and Olha Deminaniuk led the team, which included Alexander Blaeser (partner, M&A), Susanne Liebel-Kotz (partner, tax), Vinzenz Sutter (associate, M&A), Kiara Sharifi (associate, M&A), Kasper Projer (associate, Dispute Resolution/International Commercial & Trade) and Anna Zellweger (associate, International Commercial & Trade).
Continue Reading
-
New MLB managers in 2026
Nine teams had managerial vacancies this offseason. All nine of those jobs are now filled.
The Rockies became the last of the nine clubs to hire a new manager on Monday, making Warren Schaeffer their full-time skipper after he served as…
Continue Reading
-
Epidemiological Update Avian Influenza A(H5N1) in the Americas Region – 24 November 2025 – PAHO/WHO
In 2020, the highly pathogenic avian influenza (HPAI) virus subtype H5N1 clade 2.3.4.4b caused an unprecedented number of deaths among wild birds and poultry in numerous countries in Africa, Asia, and Europe. In 2021, this virus spread through…
Continue Reading
-
Focused ultrasound combined with chemotherapy improves survival in glioblastoma patients
Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40 percent increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers. This is the first time researchers have demonstrated a potential survival benefit from using focused ultrasound to open the blood-brain barrier to improve delivery of chemotherapy to the tumor site in brain cancer patients after surgery.
Our results are very encouraging. Using focused ultrasound to open the blood-brain barrier and deliver chemotherapy could significantly increase patient survival, which other ongoing studies are seeking to confirm and expand.”
Graeme Woodworth, MD, study principal investigator, Professor and Chair of Neurosurgery at UMSOM and Neurosurgeon-In-Chief at the University of Maryland Medical Center (UMMC)
The findings of this groundbreaking safety, feasibility, and comparative trial involved glioblastoma patients who were given focused ultrasound to open their blood-brain barrier before getting chemotherapy; they were matched to a rigorously selected control group of 185 glioblastoma patients with similar characteristics who received the standard dose of the chemotherapy drug, temozolomide, without receiving focused ultrasound. Trial participants were initially treated with surgery to remove their brain tumor, followed by six weeks of chemotherapy and radiation, and up to six monthly focused-ultrasound treatments plus temozolomide.
Results were published in the journal Lancet Oncology and show that trial participants had nearly 14 months of median progression-free survival, compared to eight months in the control group. In terms of overall survival, trial participants, on average, lived for more than 30 months compared to 19 months in the control group.
The study builds on more than a decade of intensive research to test the safety and feasibility of opening the blood-brain barrier using focused ultrasound first in animal studies and then in patients. It was led by Dr. Woodworth and was conducted at UMMC and four other clinical sites affiliated with the University of Toronto, Harvard University, University of Virginia, and West Virginia University. “We also demonstrated that this could be a useful technique that enables us to better monitor patients to determine if their brain cancer has progressed,” said Dr. Woodworth, who also serves as Director of the Brain Tumor Program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).
He and his team demonstrated that opening the blood-brain barrier facilitated the use of a
“liquid biopsy,” which is a blood test that detects cancer biomarkers, which can include DNA fragments, proteins and other components from the liquid environment surrounding the tumor site.Such biomarkers have been used in other cancers to determine whether the tumor has remained stable or has the potential to progress or even metastasize. Up until now, however, these tests have not been utilized in brain cancer patients since most components can never pass into the bloodstream from the brain due to the blood-brain barrier.
“These liquid biomarkers were found to be closely concordant with the patient outcomes over time, progression-free survival and overall survival,” said Dr. Woodworth.While temozolomide is the standard treatment for glioblastoma, the drug typically gets blocked by the blood-brain barrier with studies showing that less than 20 percent reaches the brain in patients. This study did not determine the exact amount of temozolomide to reach the brain in each patient, but earlier studies have shown that opening the blood-brain barrier before delivering chemotherapy can dramatically increase the amount that gets to the original tumor site.
Glioblastoma is the most common and deadliest type of malignant brain tumor. The five-year survival rate is only 5.5 percent, and patients live an average of 14 to 16 months after diagnosis when treated with surgery, radiation, and chemotherapy when appropriate. The malignancy nearly always recurs even after it is removed due to residual infiltrating cancer cells that remain after treatment.
The blood-brain barrier is a specialized network of vascular and brain cells that acts as the brain’s security system to protect against invasion by dangerous toxins and microbes. It can be opened temporarily using a specialized focused ultrasound device. This process starts with injecting microscopic inert gas-filled bubbles into the patient’s bloodstream. Guided by an MRI, precise brain regions are targeted while the injected microbubbles are circulating.
“Upon excitation under low-intensity ultrasound waves, the microbubbles oscillate within the energy field, causing temporary mechanical perturbations in the walls of the brain blood vessels,” said Pavlos Anastasiadis, PhD, an Assistant Professor of Neurosurgery at UMSOM who is an expert in ultrasound biophysics.
Prior studies led by Dr. Woodworth and this trial’s co-investigators showed that opening the blood-brain barrier temporarily can be safely and feasibly performed in brain tumor patients. He and his team conducted this procedure in the first brain cancer patient in the U.S. in 2018 at UMMC after the US Food and Drug Administration (FDA) approved the inaugural clinical trial.
“Dr. Woodworth’s findings are deeply exciting and a significant step forward for the field,” said Taofeek K. Owonikoko, MD, PhD, UMGCCC Executive Director. “Patients with glioblastoma have had few effective treatment options, and UMGCCC is proud to be at the forefront of efforts to bring hope to these patients and their families.”
Future trials could use focused ultrasound alongside other chemotherapy agents to test the effectiveness of drugs never used in brain cancer due to their ineffectiveness at crossing the blood-brain barrier.
“This groundbreaking trial has provided a potential new prognostic and therapeutic paradigm for the 15,000 Americans who are diagnosed every year with this deadly form of brain cancer,” said UMSOM Dean Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Vice President for Medical Affairs at University of Maryland, Baltimore. “The release of biomarkers into the bloodstream offers a possible new method for simple and routine monitoring of brain regions without the need for invasive biopsies. Having the ability to open the blood-brain barrier could also usher in the testing of new therapeutics to see whether they offer further life-extending benefits.”
“For the thousands of people who receive this devastating diagnosis each year, the significance of this advancement cannot be overstated,” said Bert W. O’Malley, MD, President and CEO of UMMC. “The success of this trial brings new momentum and further accelerates investigation of targeted therapies for glioblastoma and other brain cancers. Hope has been redefined for these families.”
Dr. Woodworth is also the co-leader of a larger diagnostics-focused pivotal focused ultrasound trial in glioblastoma patients called LIBERATE (NCT05383872) in partnership with ReFOCUSED (The Research Consortium for Transcranial Focused UltraSound-Enhanced Drug Delivery & Diagnostics.) ReFOCUSED is a growing group of researchers from over 20 sites across North America whose goal is to use the new opportunities offered by MRI-guided focused ultrasound to improve the clinical outcomes of brain diseases. The LIBERATE trial is currently closed to enrollment.
This trial was funded by the device manufacturer Insightec Inc. (Miami, FL), an MRI-guided focused ultrasound device company, and the National Institutes of Health (NIH) (R21NS113016).
Source:
University of Maryland School of Medicine
Journal references:
Woodworth, G. F., et al. (2025) Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology. DOI: 10.1016/S1470-2045(25)00492-9. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00492-9/fulltext
Continue Reading
-
‘Mental model’ approach shown to reduce effects of misinformation about mRNA vaccines
Correcting misinformation after it has gone viral is a common way of informing the public that what they’ve encountered may be inaccurate, lack context, be unproven, or be demonstrably false. But repeating a misconception when…
Continue Reading
-
Resurgence of malaria in the Amhara Region, Ethiopia (2014–2024): trends, spatial expansion, and control challenges | Malaria Journal
WHO. World malaria report 2024: addressing inequity in the global malaria response. Geneva: World Health Organization; 2024.
U.S. President’s Malaria Initiative (PMI). Ethiopia: malaria operational plan FY 2024. Washington DC: United States Agency for International Development (USAID); 2024.
WHO. Disease outbreak news: malaria in Ethiopia 2024 update. Geneva: World Health Organization; 2024.
Federal Ministry of Health of Ethiopia. Malaria elimination strategic plan 2021–2025. Addis Ababa: Federal Ministry of Health of Ethiopia; 2020.
Taffese HS, Hemming-Schroeder E, Koepfli C, Tesfaye G, Lee MC, Kazura J, et al. Malaria epidemiology and interventions in Ethiopia from 2001 to 2016. Infect Dis Poverty. 2018;7:103.
Google Scholar
Alemu K, Worku A, Berhane Y, Kumie A. Spatiotemporal clusters of malaria cases at village level, northwest Ethiopia. Malar J. 2014;13:223.
Google Scholar
Ministry of Health. National malaria elimination programme. Addia Ababa: Ministry of Health; 2021.
Zhou G, Taffese HS, Zhong D, Wang X, Lee MC, Degefa T, et al. Resurgence of clinical malaria in Ethiopia and its link to Anopheles stephensi invasion. Pathogens. 2024;13:748.
Google Scholar
Emiru T, Getachew D, Murphy M, Sedda L, Ejigu LA, Bulto MG, et al. Evidence for a role of Anopheles stephensi in the spread of drug- and diagnosis-resistant malaria in Africa. Nat Med. 2023;29:3203–11.
Google Scholar
Balkew M, Mumba P, Dengela D, Yohannes G, Getachew D, Yared S, et al. Geographical distribution of Anopheles stephensi in eastern Ethiopia. Parasit Vectors. 2020;13:35.
Google Scholar
Merga H, Degefa T, Birhanu Z, Abiy E, Lee MC, Yan G, et al. Urban malaria and its determinants in eastern Ethiopia: the role of Anopheles stephensi and urbanization. Malar J. 2024;23:303.
Google Scholar
Sedda L, QiQ TAJ. A geostatistical analysis of the association between armed conflicts and Plasmodium falciparum malaria in Africa. Malar J. 2015;14:500.
Google Scholar
Teka H, Golassa L, Medhin G, Balkew M, Sisay C, Gadisa E, et al. Trend analysis of malaria in urban settings in Ethiopia from 2014 to 2019. Malar J. 2023;22:235.
Google Scholar
Tadesse FG, Ashine T, Teka H, Esayas E, Messenger LA, Chali W, et al. Anopheles stephensi mosquitoes as vectors of Plasmodium vivax and falciparum, Horn of Africa, 2019. Emerg Infect Dis. 2021;27:603–7.
Google Scholar
Brhane BG, Fola AA, Nigussie H, Leonetti A, Kassa M, Hailgiorgis H, et al. Rising prevalence of Plasmodium falciparum artemisinin partial resistance mutations in Ethiopia. Commun Med. 2025;5:297.
Google Scholar
World Health Organization. World malaria report. Geneva: World Health Organization; 2022.
Hay SI, Cox J, Rogers DJ, Randolph SE, Stern DI, Shanks GD, et al. Regional warming and malaria resurgence. Nature. 2002;420:627–8.
Zhou G, Minakawa N, Githeko AK, Yan G. Climate variability and malaria epidemics in the highlands of East Africa. Trends Parasitol. 2005;21:54–6.
Google Scholar
Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, et al. Malaria resurgence: a systematic review and assessment of its causes. Malar J. 2012;11:122.
Google Scholar
Raouf S, Mpimbaza A, Kigozi R, Sserwanga A, Rubahika D, Katamba H, et al. Resurgence of malaria following discontinuation of indoor residual spraying of insecticide in an area of Uganda with previously high-transmission intensity. Clin Infect Dis. 2017;65:453–60.
Google Scholar
Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, et al. The potential public health consequences of COVID-19 on malaria in Africa. Nat Med. 2020;26:1411–6.
Google Scholar
Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, et al. Identifying and combating the impacts of COVID-19 on malaria. BMC Med. 2020;18:239.
Google Scholar
Minwuyelet A, Eshetu T, Milikit D, Aschale Y. Prevalence and risk factors of asymptomatic Plasmodium infection in Gondar Zuria District, Northwest Ethiopia. Infect Drug Resist. 2020;13:3969–75.
Google Scholar
Solomon A, Kahase D, Alemayehu M. Trend of malaria prevalence in Wolkite health center: an implication towards the elimination of malaria in Ethiopia by 2030. Malar J. 2020;19:112.
Google Scholar
Minwuyelet A, Abiye M, Zeleke AJ, Getie S. Plasmodium gametocyte carriage in humans and sporozoite rate in anopheline mosquitoes in Gondar Zuria District, Northwest Ethiopia. PLoS ONE. 2024;19:e0306289.
Google Scholar
Yalew AW. Achievements, gaps, and emerging challenges in controlling malaria in Ethiopia. Front Trop Dis. 2022;2:771030.
Dembélé L, Franetich J-F, Lorthiois A, Gego A, Zeeman A-M, Kocken CH, et al. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat Med. 2014;20:307–12.
Google Scholar
Minwuyelet A, Yewhalaw D, Atenafu G. Retrospective analysis of malaria prevalence over ten years (2015–2024) at Bichena Primary Hospital, Amhara region, Ethiopia. PLoS ONE. 2025;20:e0322570.
Google Scholar
Moltot T, Bekele G, Gebreegziabher ZA, Lemma T, Sisay M, Silesh M, et al. A five-year malaria surveillance data analysis of North Shewa zone, Amhara region, Ethiopia: July 2018 to June 2023. Malar J. 2024;23:187.
Google Scholar
Abere A, Ayalew S, Wondale B, Tigabu F, Gizachew N, Tesfaye T, et al. Dynamic shift of malaria cases in northwest Ethiopia: a 10-year retrospective cohort data analysis from 2012 to 2021. Front Malar. 2025;3:1460491.
Nigussie TZ, Zewotir TT, Muluneh EK. Seasonal and spatial variations of malaria transmissions in northwest Ethiopia: evaluating climate and environmental effects using generalized additive model. Heliyon. 2023;9:e15252.
Google Scholar
World Health Organization. Malaria surveillance, monitoring & evaluation: a reference manual. Geneva: World Health Organization; 2018.
Central Statistical Agency (CSA) of Ethiopia. Population projection of Ethiopia for all regions at Wereda level from 2014–2017. Addis Ababa: CSA; 2013.
NASA Shuttle Radar Topography Mission Global 1 arc second number. NASA Land Processes Distributed Active Archive Center. 2013.
Central Statistical Agency of Ethiopia. Population and housing census 2023/2024: Amhara Region. Addis Ababa: CSA; 2024.
Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–51.
Google Scholar
Duyar İ. A Bayesian approach in model selection. Ankara Univ J Fac Educ Sci (JFES). 1995;28(1):95–106.
WHO. World malaria report 2017. Geneva: World Health Organization; 2017.
USAID President’s Malaria Initiative. Ethiopia malaria operational plan FY 2023. Washington, DC: USAID; 2023.
EPHI. Ethiopia national malaria indicator survey 2015. Addis Ababa: Ethiopian Public Health Institute; 2016.
Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–11.
Google Scholar
World Health Organization. World malaria report. Geneva: World Health Organization; 2023.
WHO. World malaria report. Geneva: World Health Organization; 2021.
Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 2020;36:560–70.
Google Scholar
Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95(6 Suppl):15–34.
Google Scholar
White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.
Google Scholar
Yenew C, Mulatu S, Alamneh A. The trend of malaria cases, positivity rate, and determinant factors in the Amhara Regional State, Ethiopia: a mixed method. Case Rep Infect Dis. 2021;2021:2131720.
Google Scholar
Ahmed A, Khogali R, Elnour M-AB, Nakao R, Salim B. Emergence of the invasive malaria vector Anopheles stephensi in Khartoum State, Central Sudan. Parasit Vectors. 2021;14:511.
Google Scholar
Haileselassie W, Parker DM, Taye B, David RE, Zemene E, Lee MC, et al. Burden of malaria, impact of interventions, and climate variability in western Ethiopia: an area with large irrigation-based farming. BMC Public Health. 2022;22:196.
Google Scholar
Gething PW, Smith DL, Patil AP, Tatem AJ, Snow RW, Hay SI. Climate change and the global malaria recession. Nature. 2010;465:342–5.
Google Scholar
Jalilian A, Ayana GM, Ashine T, Hailemeskel E, Ebstie YA, Molla E, et al. Waning success: a 2013–2022 spatial and temporal trend analysis of malaria in Ethiopia. Infect Dis Poverty. 2024;13:93.
Google Scholar
Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, et al. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012;9:e1001165.
Google Scholar
World Health Organization. Consolidated guidelines for malaria. Geneva: World Health Organization; 2021.
Shretta R, Avancena AL, Hatefi A. The economics of malaria control and elimination: a systematic review. Malar J. 2016;15:593.
Google Scholar
Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis. 2009;200:1509–17.
Google Scholar
Cox J, Craig M, Le Sueur D, Sharp B. Mapping malaria risk in the highlands of Africa. Durban: MARA/HIMAL Technical Report; 1999.
Lindsay SW, Martens WJ. Malaria in the African highlands: past, present and future. Bull World Health Organ. 1998;76:33–45.
Google Scholar
Continue Reading
-
Olympic gymnastics champion Max Whitlock says “I’m back.”
Three-time Olympic champion Max Whitlock of Great Britain announced Monday (24 November) his return to the sport with an eye on the Olympic Games LA28.
“I said Paris will be my last ever competition, but something just isn’t sitting right,”…
Continue Reading
-
Learn New Languages This Holiday with 60% Off Rosetta Stone’s Lifetime Subscription
The holidays are quickly approaching, and if you’re like me, you’re already struggling to come up with gift ideas for those hard-to-buy-for people on your list. Why not give them a gift that keeps on giving? The gift of a new language. If you…
Continue Reading
-
Associated factors for birth-related post-traumatic stress symptoms using a birth-specific measurement: a cross-sectional study | BMC Pregnancy and Childbirth
MATERNAL NEWBORN, CHILD AND ADOLESCENT HEALTH AND, AGEING [Internet]. World Health Organization. 2023 [cited 20230109]. Available from:
Continue Reading